BETHESDA, Md., Nov. 21, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces financial results for the quarter ended September 30, 2016.
Total revenue was $162,163 for the three months ended September 30, 2016, as compared to $2,055,585 for the three months ended September 30, 2015. For the three months ended September 30, 2016, the revenue was primarily generated from the renting of heavy equipment and from managing the ongoing construction of the hotel in Genting. The decrease in revenue is attributable to the planned curtailment of the electronic trading business.
Selling, general and administrative expenses were $339,585 for the quarter ended September 30, 2016 as compared to $525,353 for the quarter ended September 30, 2015. Most of these expenses were public company related costs.
The Company reported a consolidated GAAP net income loss of $583,871 and a GAAP EPS loss of $0.02 for the three months ended September 30, 2016 compared to a GAAP net income loss of $623,373 and a GAAP EPS loss of $0.04 for the three months ended September 30, 2015.
For the quarter ended September 30, 2016, our non-GAAP cash burn was approximately $252,325 after adjusting for $97,842 of depreciation, $40,075 of non-cash interest and $193,629 of certain one-time charges.
At the end of September 30, 2016, our cash and cash equivalents along with restricted cash was $939,285 with working capital of $60,236.
“We are pleased with our progress in our specialty IP unit as we strive to develop phytocannabinoid-based therapies in major market indications. In the coming quarters, we will further delineate the pathways to assess our compounds with the goal of commencing pre-clinical trials as appropriate. Internationally, our acquisition of Cabaran Ultima has provided real estate management expertise to drive the development of high-end luxury complexes as exemplified by our 10% stake in the $262 MM Genting Highlands project,” stated Ram Mukunda, CEO.
About IGC
In the United States, we develop phytocannabinoid-based therapies. We have several patent filings for the indications of Pain, Medical Refractory Epilepsy and Cachexia using phytocannabinoids. In addition, we engage in leasing, trading, developing and managing infrastructure, and real estate projects. We are based in Bethesda, Maryland.
Our website: www.igcinc.us. Twitter @IGCIR Facebook.com/IGCIR/
Forward-looking Statements
Some of the statements contained in this press release that are not historical facts constitute forward-looking statements under the federal securities laws. Forward-looking statements can be identified by the use of the words "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "intends," "potential," "proposed" or the negative of those terms. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond IGC's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in IGC's business and acquisition and diversification strategy, competitive environment, infrastructure demands, and governmental, regulatory, political, economic, legal and social conditions in, among other places, China and India. Except as required by federal securities laws, IGC undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information or future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward-looking statements have been discussed in greater detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Financials to Follow
| INDIA GLOBALIZATION CAPITAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS | ||||||||
| All amounts in USD except share data | ||||||||
| As of | ||||||||
| 30-September - 16 | 31-March - 16 | |||||||
| (unaudited) | (audited) | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 939,285 | $ | 1,490,693 | ||||
| Accounts receivable, net of allowances | 653,959 | 962,658 | ||||||
| Inventories | 58,647 | 162,091 | ||||||
| Prepaid expenses and other current assets | 1,272,426 | 1,226,507 | ||||||
| Total current assets | $ | 2,924,317 | $ | 3,841,949 | ||||
| Goodwill | 198,170 | 1,180,951 | ||||||
| Intangible Assets | 113,321 | 113,321 | ||||||
| Property, plant and equipment, net | 6,929,982 | 7,074,437 | ||||||
| Investments in affiliates | 2,603,411 | 609,148 | ||||||
| Investments-others | 5,230,264 | 5,175,392 | ||||||
| Deferred Income taxes | 356,619 | 356,684 | ||||||
| Other non-current assets | 504,065 | 507,300 | ||||||
| Total long-term assets | $ | 15,935,832 | $ | 15,017,233 | ||||
| Total assets | $ | 18,860,149 | $ | 18,859,182 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Short -term borrowings | $ | - | $ | 27,762 | ||||
| Trade payables | 456,783 | 330,631 | ||||||
| Accrued expenses | 90,045 | 300,111 | ||||||
| Loans – others | - | 189,680 | ||||||
| Notes payable | 1,800,000 | 1,800,000 | ||||||
| Other current liabilities | 517,253 | 550,877 | ||||||
| Total current liabilities | $ | 2,864,081 | $ | 3,199,061 | ||||
| Long - term borrowings | 653,753 | 801,467 | ||||||
| Loans – others | 366,669 | - | ||||||
| Other non-current liabilities | 150,751 | 910,583 | ||||||
| $ | 1,171,173 | $ | 1,712,050 | |||||
| Total liabilities | $ | 4,035,254 | $ | 4,911,111 | ||||
| Stockholders’ equity: | ||||||||
| Common stock — $.0001 par value; 150,000,000 shares authorized; 23,265,531 issued and outstanding as of March 31, 2016 and 23,957,827 issued and outstanding as of September 30, 2016. | $ | 2,396 | $ | 2,327 | ||||
| Additional paid-in capital | 67,820,860 | 65,885,243 | ||||||
| Accumulated other comprehensive income/(loss) | (2,307,769 | ) | (2,269,357 | ) | ||||
| Retained earnings (Deficit) | (51,111,225 | ) | (50,142,199 | ) | ||||
| Total equity attributable to Parent | $ | 14,404,262 | $ | 13,476,014 | ||||
| Non-controlling interest | $ | 420,633 | $ | 472,057 | ||||
| Total stockholders’ equity | $ | 14,824,895 | $ | 13,948,071 | ||||
| Total liabilities and stockholders’ equity | $ | 18,860,149 | $ | 18,859,182 | ||||
These interim financial statements should be read in conjunction with the financial statements and notes included in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and Annual Report on Form 10-K for the fiscal year ended March 31, 2016. Quarterly financial results may not be indicative of the financial results for the entire fiscal year.
| INDIA GLOBALIZATION CAPITAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||||||||||
| All amounts in USD except share data | All amounts in USD except share data | |||||||||||||||
| Three months ended September 30, | Six months ended September 30, | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Revenues | $ | 162,163 | $ | 2,055,585 | $ | 237,563 | $ | 3,914,394 | ||||||||
| Cost of revenues (excluding depreciation) | (90,534 | ) | (1,889,598 | ) | (154,589 | ) | (3,544,367 | ) | ||||||||
| Selling, general and administrative expenses | (339,585 | ) | (525,353 | ) | (636,802 | ) | (830,756 | ) | ||||||||
| Depreciation | (97,842 | ) | (148,855 | ) | (195,514 | ) | (304,829 | ) | ||||||||
| Loss on investments / associates /joint ventures | (183,835 | ) | - | (183,835 | ) | - | ||||||||||
| Operating income (loss) | $ | (549,633 | ) | $ | (508,221 | ) | $ | (933,177 | ) | $ | (765,558 | ) | ||||
| Interest expense | (51,410 | ) | (67,460 | ) | (89,956 | ) | (128,682 | ) | ||||||||
| Interest income | 114 | - | 114 | 2 | ||||||||||||
| Other income, net (loss) | 11,985 | (64,671 | ) | 13,740 | (99,728 | ) | ||||||||||
| Income before income taxes and minority interest attributable to non-controlling interest | $ | (588,944 | ) | $ | (640,352 | ) | $ | (1,009,279 | ) | $ | (993,966 | ) | ||||
| Income taxes benefit/ (expense) | - | - | - | - | ||||||||||||
| Net income/(loss) | $ | (588,944 | ) | $ | (640,352 | ) | $ | (1,009,279 | ) | $ | (993,966 | ) | ||||
| Non-controlling interests in earnings of subsidiaries | (5,073 | ) | (16,979 | ) | (11,239 | ) | 12,106 | |||||||||
| Net income / (loss) attributable to common stockholders | $ | (583,871 | ) | $ | (623,373 | ) | $ | (998,040 | ) | $ | (1,006,072 | ) | ||||
| Earnings/(loss) per share attributable to common stockholders: | ||||||||||||||||
| Basic | $ | (0.02 | ) | $ | (0.04 | ) | $ | (0.04 | ) | $ | (0.07 | ) | ||||
| Diluted | $ | (0.02 | ) | $ | (0.04 | ) | $ | (0.04 | ) | $ | (0.07 | ) | ||||
| Weighted-average number of shares used in computing earnings per share amounts: | ||||||||||||||||
| Basic | 23,636,403 | 14,995,130 | 23,636,403 | 14,995,130 | ||||||||||||
| Diluted | 23,636,403 | 14,995,130 | 23,636,403 | 14,995,130 | ||||||||||||
These interim financial statements should be read in conjunction with the financial statements and notes included in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and Annual Report on Form 10-K for the fiscal year ended March 31, 2016. Quarterly financial results may not be indicative of the financial results for the entire fiscal year.